All News Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
36,950 ^KRW	-0.94%		+10.13%	-16.59%

May. 03	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI
Mar. 06	Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	May. 03	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	23-06-13	AQ
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	23-06-13	AQ
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	23-06-11	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	23-05-01	AQ
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth	23-03-30	AQ
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program	23-03-16	AQ
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities	23-02-13	AQ
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.	23-02-12	CI
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.	23-02-09	CI
Immune Thrombocytopenia Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain	22-12-09	AQ
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update	22-11-16	AQ
HanAll Biopharma's Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China	22-10-11	AQ
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	22-10-11	CI
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	22-10-04	CI
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update	22-08-01	AQ
Hanall Biopharma : Decision on Disposal of Treasury Stock	22-06-23	PU
Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.	22-06-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

All News

Filters